Progen Co Ltd
296160
Company Profile
Business description
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.
Contact
172 Magokjungang-ro
7th Floor, Bio Innovation Park
Gangseo-gu
Seoul
KORT: +82 260982800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
50
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,140.50 | 11.00 | 0.12% |
| CAC 40 | 7,674.78 | 24.14 | -0.31% |
| DAX 40 | 23,596.98 | 173.35 | -0.73% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,208.21 | 8.66 | -0.09% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
| NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |